VE-303
spdr s&p biotech,ishares biotechnology,PureTech Health
['$ibb', '$xbi']
vedanta biosciences earns fast track designation from for ve-303 and announces phase 2 data presentation at digestive disease week more info: $xbi $ibb $xph $pph 
BioPharma/Biotech Intel.  Daily $XBI $XPH Market Movers

Database: https://t.co/IBOqbSoYuc
Clinical trial tools: https://t.co/A77u9Q84Dc  http://globalclinicalt